| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
REVIEW |
Correspondence to:
Dr M A Dyer
St Jude Children’s Research Hospital, Department of Developmental Neurobiology, Memphis, TN 38105, USA; michael.dyer{at}stjude.org; http://www.stjude.org/dyer/
ABSTRACT
Targeted cancer treatments rely on understanding signalling cascades, genetic changes, and compensatory programmes activated during tumorigenesis. Increasingly, pathologists are required to interpret molecular profiles of tumour specimens to target new treatments. This is challenging because cancer is a heterogeneous disease—tumours change over time in individual patients and genetic lesions leading from preneoplasia to malignancy can differ substantially between patients. For childhood tumours of the nervous system, the challenge is even greater, because tumours arise from progenitor cells in a developmental context different from that of the adult, and the cells of origin, neural progenitor cells, show considerable temporal and spatial heterogeneity during development. Thus, the underlying mechanisms regulating normal development of the nervous system also need to be understood. Many important advances have come from model mouse genetic systems. This review will describe several mouse models of childhood tumours of the nervous system, emphasising how understanding the normal developmental processes, combined with mouse models of cancer and the molecular pathology of the human diseases, can provide the information needed to treat cancer more effectively.
Keywords: retinoblastoma; medulloblastoma; neuroblastoma; retrovirus; xenograft
Abbreviations: APC, adenomatous polyposis coli; CNS, central nervous system; E, embryonic day; EGL, external germinal layer; GSK-3ß, glycogen synthase kinase 3ß; Lig4, DNA ligase IV; P, postnatal day; PARP, poly (ADP-ribose) polymerase; SCID, severe combined immunodeficiency disorder; TCF/LEF, T cell factor/lymphoid enhancer factor
This article has been cited by other articles:
|
|
 |
|
  H C Moore, K M Wood, M S Jackson, M A Lastowska, D Hall, H Imrie, C P F Redfern, P E Lovat, F Ponthan, K O'Toole, et al. Histological profile of tumours from MYCN transgenic mice J. Clin. Pathol., October 1, 2008; 61(10): 1098 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cui, J. Ma, J. Ding, T. Li, G. Alam, and H.-F. Ding Bmi-1 Regulates the Differentiation and Clonogenic Self-renewal of I-type Neuroblastoma Cells in a Concentration-dependent Manner J. Biol. Chem., November 10, 2006; 281(45): 34696 - 34704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Shu, B. Antalffy, J. M. F. Su, A. Adesina, C.-N. Ou, T. Pietsch, S. M. Blaney, C. C. Lau, and X.-N. Li Valproic Acid Prolongs Survival Time of Severe Combined Immunodeficient Mice Bearing Intracerebellar Orthotopic Medulloblastoma Xenografts Clin. Cancer Res., August 1, 2006; 12(15): 4687 - 4694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mendrzyk, B. Radlwimmer, S. Joos, F. Kokocinski, A. Benner, D. E. Stange, K. Neben, H. Fiegler, N. P. Carter, G. Reifenberger, et al. Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma J. Clin. Oncol., December 1, 2005; 23(34): 8853 - 8862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Laurie, J. K. Gray, J. Zhang, M. Leggas, M. Relling, M. Egorin, C. Stewart, and M. A. Dyer Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma Clin. Cancer Res., October 15, 2005; 11(20): 7569 - 7578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Torkin, J.-F. Lavoie, D. R. Kaplan, and H. Yeger Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma Mol. Cancer Ther., January 1, 2005; 4(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
